期刊
JOURNAL OF CLINICAL ONCOLOGY
卷 23, 期 36, 页码 9208-9218出版社
AMER SOC CLINICAL ONCOLOGY
DOI: 10.1200/JCO.2005.03.2151
关键词
-
类别
资金
- Medical Research Council [MC_U122861381] Funding Source: researchfish
- MRC [MC_U122861381] Funding Source: UKRI
- Medical Research Council [MC_U122861381] Funding Source: Medline
Purpose: To perform an open-label, randomized, controlled trial comparing treatment with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) with two multidrug regimens (MDRs) for advanced Hodgkin's lymphoma (HL). Patients and Methods: Eight hundred seven patients with advanced HL (stage III to IV, or earlier stage with systemic symptoms or bulky disease) were randomly assigned between ABVD and MDR specified before randomization as alternating chlorambucil, vinblastine, procarbazine, and prednisolone (ChIVPP) with prednisolone, doxorubicin, bleomycin, vincristine, and etoposide (PABIOE), or hybrid ChIVPP/etoposide, vincristine, and doxorubicin (EVA). Radiotherapy was planned for incomplete response or initial bulk disease. Results: At 52 months median follow-up, 212 event-free survival (EFS) events (disease progression or any death) were reported. In the primary comparison, at 3 years EFS was 75% (95% Cl, 71 % to 79%) for ABVD and 75% (95% Cl, 70% to 79%) for MDRs (hazard ratio [HR] = 1.05; 95% Cl, 0.8 to 1.37; HR more than 1.0 favors ABVD). The 3-year overall survival (OS) rates were 90% (95% Cl, 87% to 93%) in patients allocated ABVD and 88% (95% Cl, 84% to 91 %) in patients allocated MDRs (HR = 1.22; 95% Cl, 0.84 to 1.77). Patients receiving MDRs experienced more grade 3/4 infection, mucositis, and neuropathy. One occurrence of myelodysplastic syndrome was reported, but no acute leukemia was reported. When the two MDRs are compared separately with ABVD, neither the alternating nor the hybrid regimen showed a statistically significant difference from ABVD for EFS or OS. Subgroup analysis suggested that MDRs may be associated with poorer outcomes in older patients (heterogeneity test of OS older or younger than 45 years, P = .020). Conclusion: There was no evidence of significant difference in EFS or OS between ABVD and MDRs in the trial overall or if the two MDR versus ABVD comparisons are considered separately. ABVD remains the standard for treatment of advanced HL.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据